Intellia Therapeutics

219 articles about Intellia Therapeutics

• Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

  11/14/2023

  Intellia Therapeutics, Inc. today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).

• Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

  11/9/2023

  Intellia Therapeutics, Inc. today reported operational highlights and financial results for the third quarter ended September 30, 2023.

• Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

  11/2/2023

  Intellia Therapeutics, Inc. presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin amyloidosis.

• Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November

  10/26/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.

• 

  Intellia Gets Phase III Greenlight from FDA for Gene Editing Therapy

  10/19/2023

  The trial, which is the first late-stage study of an in vivo CRISPR treatment in the U.S., will start by the end of 2023. Intellia's NTLA-2001 is a treatment candidate for transthyretin amyloidosis cardiomyopathy.

• Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

  10/18/2023

  Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

• Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

  10/13/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).

• 

  Regeneron, Intellia Expand CRISPR Pact to Neurological and Muscular Diseases

  10/4/2023

  The companies are expanding their long-standing CRISPR/Cas9 gene editing collaboration for the second time, now seeking to target neurological and muscular conditions.

• Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

  10/3/2023

  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.

• Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

  8/3/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the second quarter ended June 30, 2023.

• Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

  7/27/2023

  Intellia Therapeutics, Inc. will present its second quarter 2023 financial results and operational highlights in a conference call on August 3, 2023, at 8 a.m. ET.

• 

  CRISPR on the Cusp: The Promise and the Pain Points

  7/10/2023

  Gene editing technologies are advancing rapidly in the clinic, with the potential first approval later this year, but challenges remain.

• Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

  6/11/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002.

• Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

  6/5/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023.

• Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

  5/31/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the acceptance of a late-breaking abstract from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study for a presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023, taking place June 9-11 in Hamburg, Germany, and virtually.

• Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

  5/4/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

• Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

  5/1/2023

  Intellia Therapeutics, Inc. today released its 2023 Corporate Responsibility report.

• Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

  4/27/2023

  Intellia Therapeutics, Inc. will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.

• Intellia Therapeutics Names Bill Chase to its Board of Directors

  4/17/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the appointment of Bill Chase, MBA, to its board of directors.

• 

  Gene Editing Therapeutics Could Hit the Market in 2023

  4/10/2023

  Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.